Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - imatinib
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp47a63fc97978537204b7a7371de13662
identifier: http://ema.europa.eu/identifier
/EU/1/12/808/001-020
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Imatinib Teva 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-47a63fc97978537204b7a7371de13662
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/12/808/001-020
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - imatinib
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Imatinib Teva is a medicine containing an active substance called imatinib. This medicine works by inhibiting the growth of abnormal cells in the diseases listed below. These include some types of cancer.
Imatinib Teva is a treatment for adults and children for:
Imatinib Teva is also a treatment for adults for:
In the rest of this leaflet, we will use the abbreviations when talking about these diseases.
If you have any questions about how Imatinib Teva works or why this medicine has been prescribed for you, ask your doctor.
Imatinib Teva will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours.
Follow all your doctor s instructions carefully, even if they differ from the general information contained in this leaflet.
Do not take Imatinib Teva
If this applies to you, tell your doctor without taking Imatinib Teva.
If you think you may be allergic but are not sure, ask your doctor for advice.
Warnings and precautions Talk to your doctor before taking Imatinib Teva:
If any of these apply to you, tell your doctor before taking Imatinib Teva.
You may become more sensitive to the sun while taking Imatinib Teva. It is important to cover sun- exposed areas of skin and use sunscreen with high sun protection factor (SPF). These precautions are also applicable to children.
During treatment with Imatinib Teva, tell your doctor straight away if you put on weight very quickly. Imatinib Teva may cause your body to retain water (severe fluid retention).
While you are taking Imatinib Teva your doctor will regularly check whether the medicine is working. You will also have blood tests and be weighed regularly.
Children and adolescents Imatinib Teva is also a treatment for children and adolescents with CML. There is no experience in children with CML below 2 years of age. There is limited experience in children with Ph-positive ALL and very limited experience in children with MDS/MPD, DFSP, GIST and HES/CEL.
Some children and adolescents taking Imatinib Teva may have slower than normal growth. The doctor will monitor the growth at regular visits.
Other medicines and Imatinib Teva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription (such as paracetamol) and including herbal medicines (such as St. John s Wort). Some medicines can interfere with the effect of Imatinib Teva when taken together. They may increase or decrease the effect of Imatinib Teva, either leading to increased side effects or making Imatinib Teva less effective. Imatinib Teva may do the same to some other medicines.
Tell your doctor if you are using medicines that prevent the formation of blood clots.
Pregnancy, breast-feeding and fertility
Driving and using machines You may feel dizzy or drowsy or get blurred vision while taking this medicine. If this happens, do not drive or use any tools or machines until you are feeling well again.
Your doctor has prescribed Imatinib Teva because you suffer from a serious condition. Imatinib Teva can help you to fight this condition.
However, always take this medicine exactly as your doctor, pharmacist or nurse has told you. It is important that you do this as long as your doctor, pharmacist or nurse tells you to. Check with your doctor, pharmacist or nurse if you are not sure.
Do not stop taking Imatinib Teva unless your doctor tells you to. If you are not able to take the medicine as your doctor prescribed or you feel you do not need it anymore, contact your doctor straight away.
How much Imatinib Teva to take
Use in adults
Your doctor will tell you exactly how many tablets of Imatinib Teva to take.
If you are being treated for CML: Depending on your condition the usual starting dose is either 400 mg or 600 mg:
400 mg to be taken as 4 tablets once a day,
600 mg to be taken as 6 tablets once a day.
If you are being treated for GIST: The starting dose is 400 mg, to be taken as 4 tablets once a day.
For CML and GIST, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment. If your daily dose is 800 mg (8 tablets), you should take 4 tablets in the morning and 4 tablets in the evening.
If you are being treated for Ph-positive ALL: The starting dose is 600 mg to be taken as 6 tablets once a day.
If you are being treated for MDS/MPD: The starting dose is 400 mg, to be taken as 4 tablets once a day.
If you are being treated for HES/CEL: The starting dose is 100 mg, to be taken as 1 tablet once a day. Your doctor may decide to increase the dose to 400 mg, to be taken as 4 tablets once a day, depending on how you respond to treatment.
If you are being treated for DFSP: The dose is 800 mg per day (8 tablets), to be taken as 4 tablets in the morning and 4 tablets in the evening.
Use in children and adolescents The doctor will tell you how many tablets of Imatinib Teva to give to your child. The amount of Imatinib Teva given will depend on your child s condition, body weight and height. The total daily dose in children and adolescents must not exceed 800 mg with CML and 600 mg with Ph+ALL. The treatment can either be given to your child as a once-daily dose or alternatively the daily dose can be split into two administrations (half in the morning and half in the evening).
When and how to take Imatinib Teva
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice:
The tablet can be divided into equal doses.
How long to take Imatinib Teva Keep taking Imatinib Teva every day for as long as your doctor tells you.
If you take more Imatinib Teva than you should If you have accidentally taken too many tablets, talk to your doctor straight away. You may require medical attention. Take the medicine pack with you.
If you forget to take Imatinib Teva
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. They are usually mild to moderate.
Some side effects may be serious. Tell your doctor straight away if you get any of the following:
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
If you get any of the above, tell your doctor straight away.
Other side effects may include:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month.
This medicine does not require any special storage conditions.
Do not use any pack that is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Imatinib Teva contains
What Imatinib Teva looks like and contents of the pack Imatinib Teva 100 mg film-coated tablets are dark yellow to brownish orange round film-coated tablets with a score line on one side. The tablet is debossed with IT and 1 at each side of the score line. The tablets are approximately 9 mm in diameter.
Imatinib Teva 100 mg film-coated tablets are available in pack sizes of 60 or 120 film-coated tablets in blisters. Imatinib Teva 100 mg film-coated tablets are available in pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Teva B.V. Swensweg 5 2031 GA Haarlem The Netherlands
Manufacturer Teva Pharmaceutical Works Private Limited Company Pallagi t Debrecen H-4Hungary
Teva Czech Industries s.r.o. Ostravska 29, c.p. 74770 Opava-Komarov Czech Republic
TEVA PHARMA, S.L.U. C/C, n. 4, Poligono Industrial Malpica 50016 Zaragoza Spain
Merckle GmbH Graf-Arco-Str. 3, 89079 Ulm Germany
Teva Operations Poland Sp. z o.o. ul. Mogilska 80, 31-546 Krakow Poland
Teva Pharma B.V. Swensweg 5,
2031 GA Haarlem The Netherlands
PLIVA Croatia Ltd. Prilaz baruna Filipovica 10000 Zagreb Croatia
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG T l/Tel: +32 38207Lietuva UAB Teva Baltics Tel: +370 52660
Te : +359 24899Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien T l/Tel: +32 38207 esk republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007Magyarorsz g Teva Gy gyszergy r Zrt. Tel: +36 12886Danmark Teva Denmark A/S Tlf: +45 44985Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 2075407Deutschland AbZ-Pharma GmbH Tel: +49 73140Nederland Teva Nederland B.V. Tel: +31 8000228Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610Norge Teva Norway AS Tlf: +47 66775
TEVA HELLAS . . : +30 2118805 sterreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970Espa a Teva Pharma, S.L.U. Tel: +34 913873Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459France Teva Sant
T l: +33 155917Portugal Teva Pharma - Produtos Farmac uticos, Lda. Tel: +351 214767Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720Rom nia Teva Pharmaceuticals S.R.L. Tel: +40 212306Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890 sland Teva Pharma Iceland ehf. S mi: +354 5503Slovensk republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267Italia Teva Italia S.r.l. Tel: +39 028917Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805
TEVA HELLAS . .
: +30 2118805Sverige Teva Sweden AB Tel: +46 42121Latvija UAB Teva Baltics fili le Latvij
Tel: +371 67323United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu Package leaflet: Information for the patient
Imatinib Teva 400 mg film-coated tablets imatinib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-47a63fc97978537204b7a7371de13662
Resource Composition:
Generated Narrative: Composition composition-en-47a63fc97978537204b7a7371de13662
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/12/808/001-020status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - imatinib
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp47a63fc97978537204b7a7371de13662
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp47a63fc97978537204b7a7371de13662
identifier:
http://ema.europa.eu/identifier
/EU/1/12/808/001-020type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Imatinib Teva 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en